Labcorp launches skin cancer assay

LabPulse.com staff writers
May 18, 2022
2021 02 22 22 44 5518 Lab Doctors Dna 400

Labcorp has launched a new assay for measuring lymphocyte-activation gene 3 (LAG-3) expression levels by immunohistochemistry (IHC) in tumor tissue of patients with melanoma.

Studies have shown that LAG-3 is an immune-oncology target with demonstrable clinical benefit in patients with melanoma. Labcorp said its LAG-3 IHC method has demonstrated performance suitable for analysis of LAG-3 immune cell expression in clinical melanoma samples in a study published May 9 in the Journal of Clinical Pathology.

The LAG-3 IHC assay is available for use in both clinical trials and patient care, the company added.

Latest in Skin Cancer
Melanoma Social
Castle Biosciences shares melanoma test study data at SSO 2024
March 26, 2024
Visit our Molecular Diagnostics Community
Sponsored
Visit our Molecular Diagnostics Community
April 5, 2024
Melanoma Social
DermTech to lay off 30 employees, take further restructuring measures
February 1, 2024
Melanoma Social
Cell-penetrating peptide selectively kills melanoma cells in study
September 8, 2023
Related Stories
Fda Button Social
Skin Cancer
FDA clears DeepX Diagnostics digital dermatoscope to screen for suspected skin cancer lesions
2019 07 11 21 34 8877 Melanoma 400
Artificial Intelligence
Unilabs selects Proscia’s DermAI to diagnose melanoma
2022 01 26 06 58 5027 Women Laboratory 400
Pathology, histology
NextCure announces data on IHC assay for solid tumors
Visit our Molecular Diagnostics Community
Sponsor Content
Visit our Molecular Diagnostics Community
More in Skin Cancer
Castle Biosciences shares melanoma test study data at SSO 2024
By LabPulse.com staff writers
Castle Biosciences shared data from two studies on the performance of its DecisionDx-Melanoma test in patients with cutaneous melanoma at the Society of Surgical Oncology 2024 (SSO 2024) annual meeting, held March 20-23 in Atlanta.
March 26, 2024
Melanoma Social
FDA grants accelerated approval to Iovance’s melanoma cell therapy
By LabPulse.com staff writers
The FDA granted accelerated approval to Iovance Biotherapeutics’ T-cell therapy treatment for unresectable or metastatic melanoma.
February 21, 2024
Melanoma Social
DermTech to lay off 30 employees, take further restructuring measures
By LabPulse.com staff writers
DermTech will lay off 30 employees and take additional restructuring measures to cut operating expenses, streamline operations, and focus its resources on revenue growth.
February 1, 2024
Melanoma Social
Cell-penetrating peptide selectively kills melanoma cells in study
By Matt Limb
Scientists have voiced fresh hopes for metastatic skin cancer therapy after identifying a way to kill melanoma cells efficiently and selectively while sparing normal cells, according to a recent study.
September 8, 2023
Melanoma Social
Castle Biosciences reports study validation for melanoma gene expression test
By Maryam Payne
The study findings support results from a recently published study which showed that patients who received routine imaging guided by high-risk 31-GEP test scores had earlier diagnoses of recurrence, which in turn led to better outcomes for patients.
July 6, 2023
Pathology Slide Melanoma Social
DermTech moves to lay off 40 people, focuses on melanoma test to reduce spending
By Nick Paul Taylor
DermTech is reducing its workforce by 15% as part of a restructuring that will see the company suspend pipeline programs and focus on growing sales of its DMT melanoma test.
June 30, 2023
Melanoma Social
FDA clears DeepX Diagnostics digital dermatoscope to screen for suspected skin cancer lesions
By LabPulse.com staff writers
The device has conducted more than 180 thousand assessments in pharmacies and primary care clinics in Europe; DeepX is poised to enter the U.S. market.
June 6, 2023
Fda Button Social
SkylineDx, NeraCare partner on melanoma test development
By LabPulse.com staff writers
They entered a co-development and licensing agreement for NeraCare’s proteomic test Immunoprint, which identifies patients with early-stage melanoma who are at high risk of progression, relapse, and death.
April 21, 2023
Melanoma Social
DermTech obtains melanoma testing coverage for additional 1.9 million people
By LabPulse.com staff writers
The skin-based genomics test is a noninvasive way to enhance melanoma detection with a greater than 99% negative predictive value, DermTech said.
March 7, 2023
Cutaneous Squamous Cell Carcinoma Skin Social
DermTech, Sonora Quest ink deal to broaden access to melanoma detection test
By LabPulse.com staff writers
Under the agreement, Sonora Quest becomes the exclusive laboratory provider in Arizona for DermTech’s melanoma test.
November 16, 2022
Cutaneous Squamous Cell Carcinoma Skin Social
Castle Biosciences reports results for gene expression tests in melanoma study
By LabPulse.com staff writers
Castle Biosciences described studies evaluating its DecisionDx-Melanoma and DecisionDx-UM gene expression profile tests, conducted in collaboration with the National Cancer Institute.
October 27, 2022
Melanoma
Biocept expands commercial availability of CSF assay to metastatic melanoma
By LabPulse.com staff writers
The new CNSide for melanoma assay uses an antibody cocktail optimized for the capture of melanoma cells based on unique cellular characteristics.
October 17, 2022
Cancer Cell Target2
Page 1 of 2
Next Page